What is BOLUOKE?

Scientific name: A proprietary enzyme mixture containing lumbrokinase extracted from earthworms (Eisenia Fetida)

Main Function

ØSupports and maintains healthy coagulation activity of the body

Physiological effects already shown in scientific literature

ØActivates plasminogen system & hydrolyzes fibrin directly

ØLowers PAI-1, fibrinogen, ESR, and C-RP levels

ØLowers whole blood viscosity & plasma viscosity

ØReduces platelet aggregation

Potential applications

Many acute and chronic conditions commonly associated with modern diet and lifestyle often lead to a hypercoagulable blood state, which means the body’s fibrinolytic activity is under-functioning relative to the body’s pro-coagulation activity. In a hypercoagulable state, these two systems are out of balance and the blood is more prone to forming excessive fibrin. Boluoke can support the body’s fibrinolytic system and bring the whole system back into a more balanced state. Hypercoagulation is not a disease, but merely a blood state that is often associated with many conditions. However, it can contribute to the progression and deterioration of many conditions if it is not brought back into balance. The causes for hypercoagulation may be inflammation, infection, trauma, toxicities, etc., and correcting the underlying causes is the long-term solution.

Major advantages

ØOral preparation; no injection required

ØSupported by many scientific and human data

ØDoes not significantly affect INR, PT, or aPTT

ØStandardized enzymatic strength

ØExcellent safety records and well tolerated

Dosage

ØMaximal effect: 2 capsules 3x per day 30 minutes before each meal for 3-6 weeks or as recommended by a physician

ØMaintenance: 1 capsule 1-3x per day 30 minutes before each meal

Contra-indications

ØRecent surgery, lumbar/arterial puncture, or trauma

ØKnown aneurysm, GI ulceration/bleeding, or any bleeding disorders

ØConcurrent administration of strong anti-platelets like Plavix, Ticlid, etc.

ØKnown allergy to lumbrokinase, earthworms or corn

Fundamental Studies on Fibrinolysis:

(1)In vitro test shows that 40mg of clot (in 37 degrees Celsius at 9 prm) can be completely dissolved by 1250u/ml Boluoke in 30 min. In contrast, Urokinase in the same concentration can only dissolve 18.9% in 30 min., and dissolve 57% in 60 min., there is still 11% cannot be dissolved at 120 min. It shows that the Boluoke can dissolve clot in vitro with far more efficacy and intensity than Urokinase (see below).

Time Elapsed

Boluoke on 40mg clot

Urokinase on 40mg clot

(37 degrees Celsius, 9 rpm)

1250 u/ml

125 u/ml

62.5 u/ml

1250 u/ml

300 u/ml

60 u/ml

30 minutes

100% dissolved

66.7% dissolved

27.5% dissolved

18.9 dissolved

N/A

N/A

60 minutes

N/A

N/A

N/A

57% dissolved

N/A

N/A

120 minutes

N/A

100 dissolved

91.3% dissolved

89% dissolved

60% dissolved

31% dissolved

(2) Researchers induced thrombus in the inferior vena cava in rodents, then gave Boluoke either 1000u/kg intravenously or 6000 u/kg rectally, and reassess the thrombosis in 2 or 4 hours. Boluoke was shown to have significant thrombolytic effect both intravenously and rectally compared to the control (see below):

Route of administration

Boluoke

Control

Ratio of Animals without thrombus

Ave. wt. of thrombi remained

Ratio of Animals without thrombus

Ave. wt. of thrombi remained

2 hrs after 10,000 u/kg of Boluoke intravenously

6/10 (60%)

2.6 +/- 1.29mg

2/11 (18.18%)

24.36 +/- 6.72mg

4 hrs after 6,000 u/kg of Boluoke rectally

9/11 (81.81%)

0.87 +/- 0.70mg

1/9 (11.11%)

12.02 +/- 4.85mg

Phamacokinetics & Pharmacodynamics:

(1)Researchers injected emboli made from radioactive 125I tagged fibrinogen into rabbit jugular veins, and induced pulmonary embolism. The rabbits were then given 2,000 u/kg or 600 u/kg of Boluoke intra-duodenally or placebo. Blood was taken at 0.5, 1, 2, 3, and 5 hours, and radioactivity were assessed.The Boluoke group showed significant increase of radioactivity after 3 hours and further increase after 5 hours compared to the placebo group, indicating marked fibrinolysis.The amount of radioactivity also seemed to be dose-dependent (see below):

Radioactivity assessed at:

2,000 u/kg Boluoke

600 u/kg Boluoke

Control

3 hours

72.9 +/- 12.0

66.7 +/- 13.1

58.1 +/- 8.6

5 hours

70.4 +/- 11.0

72.6 +/- 18.4

52.2 +/- 11.2

(2)Rabbits were given 5,000 u/kg of Boluoke intravenously, 5 minutes after the euglobulin lysis time (ELT) was shortened from 102 +/- 15 to 15 +/- 2 minutes. When rabbits were given 2,500 u/kg intravenously, 15 minutes after the ELT was shortened from 102 +/- 15 to 42 +/- 17 minutes.

(3)When rabbits were given 4,000 u/kg of Boluoke orally, ELT started to decrease 3 hours afterwards. At 4 hours post-administration ELT had shorted from 335 +/- 38 to 240 +/- 36 minutes. The ELT dropped to the lowest 8 hours post-administration at 203 +/- 35 minutes. At 12 hours the ELT was back to pre-medication level.

The conclusion of the studies above indicate that Boluoke’s effect peaks between 5-8 after oral administration, thus the optimal way to dose Boluoke is 3 times daily.